Malignant lymphoma Cancer Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
Conditions
Interventions
All newly diagnosed lymphoma patients at Karolinska University Hospital are asked to participate. Participation involves the collection of tumour material for genetic analysis (using a lymphoma panel
Sponsors
Karolinska University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Newly diagnosed adult (aged 18 years or above) lymphoma patients
Exclusion criteria
Exclusion criteria: Does not meet inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number and type of genetic driver mutations potentially relevant for diagnosis, prognosis and treatment prediction, assessed by next-generation sequencing (NGS) for each tumour case at diagnosis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Progression-free survival, assessed using data from medical records, the Swedish lymphoma register and Swedish cause-of-death register from the date of study inclusion to relapse, death or end of follow-up 2. Overall survival assessed using the Swedish cause-of-death register from the date of study inclusion to death or end of follow-up 3. Level of cell-free tumour DNA measured quantitatively using haploid genome equivalents per ml of plasma at diagnosis, after the first treatment, at interim analysis, end-of-treatment and once yearly 4. Quality of life assessed using the EORTC QLQ-30 questionnaire at diagnosis and at 1, 2 and 5 years after diagnosis | — |
Countries
Sweden
Outcome results
None listed